110 related articles for article (PubMed ID: 10596358)
1. In vitro conditions for the study of the in vivo performance of sustained-release theophylline matrix tablets administered in fasted conditions and with a high-fat diet.
Andonaegui MT; Barría JL; Thielemann AM; Seitz C; Gai MN
Drug Dev Ind Pharm; 1999 Nov; 25(11):1199-203. PubMed ID: 10596358
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the effect of 3 different diets on the bioavailability of 2 sustained release theophylline matrix tablets.
Gai MN; Isla A; Andonaegui MT; Thielemann AM; Seitz C
Int J Clin Pharmacol Ther; 1997 Dec; 35(12):565-71. PubMed ID: 9455715
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo sustained-release characteristics of theophylline matrix tablets and novel cluster tablets.
Hayashi T; Kanbe H; Okada M; Kawase I; Ikeda Y; Onuki Y; Kaneko T; Sonobe T
Int J Pharm; 2007 Aug; 341(1-2):105-13. PubMed ID: 17512147
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the in vitro and in vivo performance of two sustained-release lithium carbonate matrix tablets. Effect of different diets on the bioavailability.
Gai MN; Ferj S; García E; Seitz C; Thielemann AM; Andonaegui MT
Drug Dev Ind Pharm; 1999 Feb; 25(2):131-40. PubMed ID: 10065346
[TBL] [Abstract][Full Text] [Related]
5. Application of fibroin in controlled release tablets containing theophylline.
Katayama H; Issiki M; Yoshitomi H
Biol Pharm Bull; 2000 Oct; 23(10):1229-34. PubMed ID: 11041257
[TBL] [Abstract][Full Text] [Related]
6. Hot-melt coating technology. I. Influence of Compritol 888 Ato and granule size on theophylline release.
Faham A; Prinderre P; Farah N; Eichler KD; Kalantzis G; Joachim J
Drug Dev Ind Pharm; 2000 Feb; 26(2):167-76. PubMed ID: 10697753
[TBL] [Abstract][Full Text] [Related]
7. Theophylline controlled-release formulations: in vivo-in vitro correlations.
Yu Z; Schwartz JB; Sugita ET
Biopharm Drug Dispos; 1996 Apr; 17(3):259-72. PubMed ID: 8983400
[TBL] [Abstract][Full Text] [Related]
8. The influence of diluent on the release of theophylline from hydrophilic matrix tablets.
Pina ME; Veiga F
Drug Dev Ind Pharm; 2000 Oct; 26(10):1125-8. PubMed ID: 11028230
[TBL] [Abstract][Full Text] [Related]
9. 'Dose dumping' and sustained-release theophylline.
Welch JS
Am Fam Physician; 1995 Oct; 52(5):1278, 1284. PubMed ID: 7572551
[No Abstract] [Full Text] [Related]
10. Release and absorption characteristics of novel theophylline sustained-release formulations: in vitro-in vivo correlation.
Hussein Z; Friedman M
Pharm Res; 1990 Nov; 7(11):1167-71. PubMed ID: 2293217
[TBL] [Abstract][Full Text] [Related]
11. Theophylline-controlled release preparations and fatty food: an in vitro study using the rotating dialysis cell method.
el-Arini SK; Shiu GK; Skelly JP
Pharm Res; 1990 Nov; 7(11):1134-40. PubMed ID: 2293211
[TBL] [Abstract][Full Text] [Related]
12. Effect of gallbladder contraction induced cholagogia on the pharmacokinetic profile of a sustained-release theophylline formulation.
Fuchs WS; von Nieciecki A; Molz KH; Popescu G; Weil A; Barkworth MF; Gay S; Laicher A; Stanislaus F
Arzneimittelforschung; 1996 Dec; 46(12):1120-6. PubMed ID: 9006785
[TBL] [Abstract][Full Text] [Related]
13. Influence of design parameters on sustained drug release properties of 3D-printed theophylline tablets.
Pflieger T; Venkatesh R; Dachtler M; Cooke K; Laufer S; Lunter D
Int J Pharm; 2024 Jun; 658():124207. PubMed ID: 38718971
[TBL] [Abstract][Full Text] [Related]
14. A new method of dissolution in vitro, the "Bio-Dis" apparatus: comparison with the rotating bottle method and in vitro: in vivo correlations.
Esbelin B; Beyssac E; Aiache JM; Shiu GK; Skelly JP
J Pharm Sci; 1991 Oct; 80(10):991-4. PubMed ID: 1784010
[TBL] [Abstract][Full Text] [Related]
15. Excipient-excipient interaction in the design of sustained-release theophylline tablets: in vitro and in vivo evaluation.
Bayomi MA; Al-Suwayeh SA; El-Helw AR
Drug Dev Ind Pharm; 2001 Jul; 27(6):499-506. PubMed ID: 11548856
[TBL] [Abstract][Full Text] [Related]
16. Improving of the accuracy of in vitro-in vivo linear correlation using kinetic models for ultra sustained release theophylline tablets.
Karasulu E; Aktogu S; Karasulu HY; Aydogdu A; Tuglular I; Ertan G
Eur J Drug Metab Pharmacokinet; 2003; 28(4):301-7. PubMed ID: 14743972
[TBL] [Abstract][Full Text] [Related]
17. [Theophylline release and diffusion from a compressed ethylcellulose matrix through an artificial membrane].
Noureddine N; Douki W; Chaumeil JC; Sfar S
Ann Pharm Fr; 2004 Sep; 62(5):343-7. PubMed ID: 15314582
[TBL] [Abstract][Full Text] [Related]
18. Eudraginated polymer blends: a potential oral controlled drug delivery system for theophylline.
Emeje M; John-Africa L; Isimi Y; Kunle O; Ofoefule S
Acta Pharm; 2012 Mar; 62(1):71-82. PubMed ID: 22472450
[TBL] [Abstract][Full Text] [Related]
19. Effect of pH on the in vitro dissolution and in vivo absorption of controlled-release theophylline in dogs.
Vashi VI; Meyer MC
J Pharm Sci; 1988 Sep; 77(9):760-4. PubMed ID: 3225770
[TBL] [Abstract][Full Text] [Related]
20. A new drug delivery system using plasma-irradiated pharmaceutical aids. V. Controlled release of theophylline from plasma-irradiated double-compressed tablet composed of a wall material containing polybenzylmethacrylate.
Ishikawa M; Noguchi T; Niwa J; Kuzuya M
Chem Pharm Bull (Tokyo); 1995 Dec; 43(12):2215-20. PubMed ID: 8582024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
